The story has been updated to clarify that the Oncotype DX breast cancer test will be conducted at Genomic Health's laboratory in California.

NEW YORK (GenomeWeb News) – Swiss-based diagnostics firm Unilabs said today that it is now offering Genomic Health's Oncotype DX breast cancer test at partner clinics and hospitals.

As part of its agreement with Genomic Health, physicians can send their patients' tissue samples to the Unilabs HIS laboratory. All tests will be sent to Genomic Health's centralized laboratory where the Oncotype DX testing will be done.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.